EGFR Protein Tyrosine Kinase Substrate

Product Description

EGFR Protein Tyrosine Kinase Substrate
Catalog number: B2011309
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 1 mg
Molecular Weight or Concentration: 1076.2 g/mol
Supplied as: Lyophilized
Applications: molecular tool for various biochemical applications
Storage: -20 °C
Keywords: EGFR Protein Tyrosine Kinase Substrate [ADEYLIPQQ]
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials Ann Oncol. 1997 Dec;8(12):1197-206.
2: Bose R, Holbert MA, Pickin KA, Cole PA. Protein tyrosine kinase-substrate interactions Curr Opin Struct Biol. 2006 Dec;16(6):668-75.
3: Tavakoli F, Ganjalikhany MR. Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase PLoS One. 2019 May 22;14(5):e0217031.
4: Willoughby LF, Manent J, Allan K, Lee H, Portela M, Wiede F, Warr C, Meng TC, Tiganis T, Richardson HE. Differential regulation of protein tyrosine kinase signalling by Dock and the PTP61F variants FEBS J. 2017 Jul;284(14):2231-2250.
5: Chang BY, Harte RA, Cartwright CA. RACK1: a novel substrate for the Src protein-tyrosine kinase Oncogene. 2002 Oct 31;21(50):7619-29.
6: Engel K, Sasaki T, Wang Q, Kuriyan J. A highly efficient peptide substrate for EGFR activates the kinase by inducing aggregation Biochem J. 2013 Aug 1;453(3):337-44.
7: Franco Nitta C, Green EW, Jhamba ED, Keth JM, Ortiz-Caraveo I, Grattan RM, Schodt DJ, Gibson AC, Rajput A, Lidke KA, Wilson BS, Steinkamp MP, Lidke DS. EGFR transactivates RON to drive oncogenic crosstalk Elife. 2021 Nov 25;10:e63678.
8: Hunter T, Cooper JA. Protein-tyrosine kinases Annu Rev Biochem. 1985;54:897-930.
9: Rosen OM. After insulin binds Science. 1987 Sep 18;237(4821):1452-8.
10: Zhai X, Ward RA, Doig P, Argyrou A. Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies Biochemistry. 2020 Apr 14;59(14):1428-1441.

Products Related to EGFR Protein Tyrosine Kinase Substrate can be found at Substrates